Life-sciences company Illumina is facing a labyrinth of antitrust hurdles on two continents as it seeks to save its planned US$7.1 billion acquisition of Grail, which is developing an early-stage cancer-detection test.
The deal, announced last September, could have important ramifications for cancer care and the future of both companies. It also has become something of a test for US and European antitrust enforcers as they focus more on whether acquisitions of leading startups could slow innovation.
The US Federal Trade Commission (FTC) sued the companies in March to block the deal. Since then, the European Union has added an element of intrigue by invoking a new policy to claim a say on whether the combination of the two US-based companies moves forward.
llumina and Grail suffered the latest in a series of legal blows late Friday, May 28, in San Diego, where a judge granted the FTC’s request to drop coming federal court proceedings, rejecting arguments from the companies that a slower legal timeline would be unfair to their defense of the transaction. Illumina is separately mounting a legal campaign overseas contesting the EU’s jurisdiction.
According to the Wall Street Journal, the FTC sees the deal differently, arguing it could harm competition in the testing market. Other cancer-test developers—Grail’s competitors—have no choice but to use Illumina’s instruments, the FTC alleged in its complaint, putting Illumina in a position to impede their efforts and “cause substantial harm to U.S. consumers, who would experience reduced innovation, as well as potentially higher costs and reduced choice and quality for these lifesaving products.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
FCC Votes to Restore Net Neutrality Rules
Apr 25, 2024 by
nhoch@pymnts.com
Apple Rejects Spotify’s Updated App Over In-App Pricing Disclosure
Apr 25, 2024 by
CPI
FCC Set to Reinstate Net Neutrality Rules Today
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI